CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
ESSAIS COMPARANT CISPLATINE ET CARBOPLATINE


Précédent Retour au menu principal  Suivant


référence

Schémas de chimiothérapie

n

st IV

% RO

p

SM

p

A. Cisplatine versus carboplatine

 

Klastersky,

1990 (1)

I. CDDP (120 mg/m2) + VP16

114

(63)

27


0,07

30 s


NS

II. CBDCA (325 mg/m2)+VP1 6

114

(61)

16

27 s

Comella,

1994 (2)

I. CDDP (60 mg/m2) + VP16+ épir.

28

(0)

62


NS

?

 

II. CBDCA (300 mg/m2) + VP16 + épir.

30

(0)

59

?

Jelic,

2001 (3)

I. CDDP (120 mg/m²) + MMC + VDS

112

(64)

36

 

NS

 

 

0.008

II. CBDCA (500 mg/m²) + MMC + VDS

107

(45)

30

 

Schiller,

2002 (4)

I.CDDP (75 mg/m²) + Paclitaxel (135 mg/m²)

303

(89%)

21

 

NS

7,8 m

 

NS

II.Carbo (AUC 6) + Paclitaxel (225 mg/m²)

299

(83%)

17

8,1 m

Rosell,

2002 (5)

I.CDDP (80 mg/m²) + Paclitaxel (200 mg/m²)

309

(178)

27

 

NS

9,8 m

 

0,02

II. CBDCA (AUC 6) + Paclitaxel (200 mg/m²)

309

(199)

24

8,2 m

Mazzanti,

2003 (6)

I. CDDP (80 mg/m²) + gemcitabine

62

(36)

42

 

NS

10 m

 

NS

II. Carboplatine (AUC 5) + gemcitabine

58

(38)

31

10,8 m

Fossella,

2003 (7)

I. Docétaxel + CDDP (75)

408

67 %

32

 

 

S

11,3 m

 

 

0,044*

II. Docétaxel + Carboplatine (AUC 6)

404

67 %

24

9,4 m

III. CDDP (100) + VNR

404

67 %

24,5

10,1 m

Zatloukal,

2003 (8)

I. CDDP (80) + gemci

87

59 %

41

 

0,09

8,7 m

 

0,9

II Carboplatine (AUC 5) + gemci

89

62 %

29

8 m

Danson,

2003 (9)

I. Carboplatine (AUC 5) + gemci

186

65 %

30

 

NS

236 j

 

0,18

II. CDDP (50) + MMC-Ifo ou MMC-VBL

186

47 %

33

248 j

Paccagnella, 2004 (10)

I. CDDP (100) + MMC + VBL

75

77%

38

 

NS

7,2 m

 

0,19

II. Carboplatine (300) + MMC + VBL

78

80%

43

10 m

Chen,

2006 (11)

I. Paclitaxel (160) + CDDP (60)

41

88 %

30

 

NS

10,5 m

 

 

II. Paclitaxel (160) + Carbo (AUC 6)

40

82 %

40

10,3 m

Langer,

2007 (12)

PS 2

I. Paclitaxel (200) + Carbo (AUC 6)

51

79 %

14

 

6.2 m

 

II Gemcitabine (1 x 2) + CDDP (60)

49

73 %

23

6.9 m

 
B. Cisplatine versus cisplatine + carboplatine

 

Sculier,

1994 (13)

I. CDDP (120 mg/m2)

56

(54)

23


NS

26 s


NS

II. CDDP (60 mg/m² + CBDCA (200 mg/m2)

53

(50)

22

28 s

Ardizzoni,

1995 (14)

I. MMC-Ifo-CDDP (80 mg/m²)

23

(15)

9

 

 

NS

 

 

II. Idem + interferon a

27

(24)

7

 

III. CDDP (60 mg/m²) + CBDCA (400 mg/m²)

43

(35)

14

 

Comella,

1996 (15)

I. CDDP (120 mg/m²) + VP16

53

(28)

28

 

NS

31 s

 

NS

II. CDDP (60 mg/m²)+ CBDCA (250 mg/m²) + VP16 + VNR

51

(29)

25

27 s

Sculier,

2000 (16)

I.MMC+Ifo+ CDDP (50 mg/m²)

147

(tous)

27

 

NS

28 s

 

NS

II.Idem + CDDP (60 mg/m²) + Carbo (200 mg/m²)

150

33

32 s

Références

       (1)                 Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990 Sep;8(9):1556-62.

       (2)    Comella P, Scoppa G, Daponte A, Musetta G, Anania C, Maiorino A, et al. Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer. Cancer 1994 Oct 1;74(7):1874-81.

       (3)    Jelic S, Mitrovic L, Radosavljevic D, Elezar E, Babovic N, Kovcin V, et al. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer 2001 Oct;34(1):1-13.

       (4)    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10;346(2):92-8.

       (5)    Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002 Oct;13(10):1539-49.

       (6)    Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003 Jul;41(1):81-9.

       (7)    Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003 Aug 15;21(16):3016-24.

       (8)                 Zatloukal P, Petruzelka L, Zemanova M, Kolek V, Skrickova J, Pesek M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003 Sep;41(3):321-31.

       (9)    Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 2003 Aug 1;98(3):542-53.

     (10)                 Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004 Jan;43(1):83-91.

     (11)    Chen YM, Perng RP, Tsai CM, Whang-Peng J. A phase II study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. J Thorac Oncol 1, 141-145. 2006.
Ref Type: Journal (Full)

     (12)    Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007 Feb 1;25(4):418-23.

     (13)    Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, et al. Phase II randomized trial comparing high-dose cisplatin with moderate- dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1994 Feb;12(2):353-9.

     (14)                 Ardizzoni A, Sertoli MR, Corcione A, Pennucci MC, Baldini E, Intra E, et al. Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study. Eur J Cancer 1990;26(9):937-41.

     (15)    Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small- cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 1996 Dec;74(11):1805-11.

     (16)    Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumohl J, et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000 Nov;83(9):1128-35.

 

 

 


Retour au début de la page